- China Pacific’s year-to-date life premium income stands at 209.59 billion yuan.
- The company has amassed a year-to-date property and casualty insurance premium income of 159.82 billion yuan.
- Analysts have issued 21 buy ratings for China Pacific.
- The firm has received 4 hold ratings from analysts.
- There are no sell ratings for China Pacific.
A look at China Pacific Insurance (Group) Co., Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
China Pacific Insurance (Group) Co., a leading insurance services provider, is forecasted to have a promising long-term outlook based on its Smartkarma Smart Scores. With a solid score of 4 in Value, Dividend, and Growth factors, the company is deemed to be well-positioned for future profitability and growth opportunities. Additionally, the Momentum score of 5 reflects a strong positive trend for the company. Despite a slightly lower score of 3 in Resilience, China Pacific Insurance (Group) Co. showcases overall strength in various key areas, signaling a favorable trajectory for its future performance.
China Pacific Insurance (Group) Co. is recognized for its robust offerings in life and property insurance products through its subsidiaries. The company’s high scores across Value, Dividend, Growth, and Momentum factors underscore its potential for sustained success and value creation in the insurance industry. With a balanced focus on both life and property insurance, China Pacific Insurance (Group) Co. stands out as a formidable player poised for growth and resilience in the long run, as per the Smartkarma Smart Scores assessment.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
